This is a routine insider sale by an officer with no material impact on the stock. Monitor for any acceleration of insider selling or a pattern of larger dispositions ahead of upcoming earnings or catalysts, but no immediate action is warranted.
INSM drugs
INSM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $115.62entry
- T+1 · 6mo ago −5.60%α −4.38% · $109.14
- T+5 · 6mo ago −5.27%α −4.55% · $109.53
- T+20 · 5mo ago −15.37%α −14.51% · $97.85
- T+60 · 3mo ago +16.55%α +12.96% · $134.75
Price Chart
How similar events traded
Executive Summary
Sara Bonstein, an officer of Insmed, filed a Form 144 on May 13, 2026, indicating intent to sell 8,272 shares of common stock through Merrill Lynch. At the current market cap of $25.1B, the proposed sale value of approximately $2.2M is modest relative to the company's size and represents a routine insider transaction. The filing does not disclose the specific role of the officer, but the sale is not flagged as a CEO/CFO disposition and follows a pattern of recent insider selling activity.
Key Facts
- Insider Sara Bonstein (officer) filed Form 144 to sell 8,272 shares of INSM common stock.
- Sale is planned through Merrill Lynch with an estimated market value of approximately $2.2M based on current price.
- Transaction date noted as May 11, 2026, with filing on May 13, 2026.
- Recent 30-day insider activity includes 3 sells totaling $1.6M, consistent with routine insider selling.
- No CEO or CFO sale indicated; the filing is a standard intent-to-sell notice.
Financial Impact
Proposed sale of 8,272 shares valued at approximately $2.2M, representing a small fraction of total insider holdings and less than 0.01% of market cap.
Risk Factors
- Potential for additional insider selling if the officer or other insiders increase dispositions.
- No material risk to the company's fundamentals from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-034690 |
| Document: 0001628280-26-034690-index.html | 0001628280-26-034690 |
| Document: 0001628280-26-034690.txt | 0001628280-26-034690 |
Track record
24 reports on INSM
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers